Health Rounds: Researchers discover key to the placebo effect in the brain
Health Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us? Forward this newsletter to them. They can also subscribe here.
By Nancy Lapid
July 25 (Reuters) -Hello Health Rounds Readers! Today we highlight three early experimental findings: a fascinating discovery that may help explain the placebo effect, which causes people to respond to fake drugs, and two discoveries that could lead to treatments for keeping breast cancer tumors from growing and colon cancer from spreading to the liver.
Scientists find site of placebo effect in brain
Neuroscientists have discovered a key piece of a puzzle to explain the placebo effect in which individuals appear to respond and feel better after receiving a fake pill or treatment, according to a report published on Wednesday in Nature.
Studying mice, the researchers found that when the animals are expecting pain relief, neurons and synapses along a pain control pathway in the brain are activated even when no medication has been given.
The pathway runs from the cingulate cortex in the front of the brain, through the pons region of the brainstem, to the cerebellum in the back of the brain.
“That neurons in our cerebral cortex communicate with the pons and cerebellum to adjust pain thresholds based on our expectations is both completely unexpected... and incredibly exciting,” study leader Greg Scherrer of the University of North Carolina said in a statement.
The pathway contains “an extraordinary abundance” of proteins called opioid receptors that play a role in pain control, Scherrer said.
Blocking the pathway interrupted the placebo effect, and activating the pathway caused pain relief even in animals that had not been trained to expect it, he added.
“Our results open the possibility of activating this pathway through other therapeutic means, such as drugs or neurostimulation methods to treat pain,” Scherrer said.
Existing drugs might curb breast tumor growth
Lab experiments on tissue samples from more than 1,500 patients suggest drugs from a class known as sodium channel blockers might help keep breast cancer at bay during the interval between diagnosis and surgery, researchers said.
The drugs have been shown in earlier test tube experiments to keep breast cancers from growing, but how they achieve that effect has not been clear.
By blocking sodium from entering the cancer cells, the drugs cut off a process that enables the cells to move out of the tumor, the researchers found.
When sodium enters the cell, the cell pumps out lactic acid, causing the local area to become more acidic. That increases the activities of enzymes that digest the material that fills the spaces between cells, freeing up room for cancer cells to spread and move out of the tumor, the researchers reported on Thursday in Oncogene.
They also found that human breast cancer tumors with more channels for sodium entry were more likely to metastasize, or spread.
The drugs still need to be tested in clinical trials to see whether targeting sodium channels in breast cancer tumors would be effective in patients.
The drugs are already used to treat conditions such as epilepsy, nerve pain, and heart rhythm disturbances, “so there is a possibility that a drug which already has a good safety profile could be repurposed for breast cancer patients on the waiting list for surgery,” study leader Will Brackenbury from the University of York in the UK said in a statement.
Commercially available sodium blockers include Tegretol (carbamazepine) from Novartis NOVN.S and Dilantin (phenytoin) from Viatris VTRS.O.
Proteins help colorectal cancer cells colonize the liver
Researchers have discovered how colorectal cancer cells manage to attach themselves so effectively to liver cells, according to a report published on Wednesday in Nature.
When colorectal cancers spread to other organs, the liver is usually the first target. Liver metastases affect up to 60% of colorectal cancer patients and are often fatal, earlier studies have shown.
In lab experiments, investigators found that proteins on the surfaces of the colorectal cancer cells and the liver cells bind together in a way that changes the cancer cells and allows them to colonize in the liver.
More specifically, when liver cells traveling in the bloodstream have a protein called Plexin-B2 and the colorectal cancer cells have proteins from the semaphorin family, the colorectal cancer cells can attach themselves to the liver cells.
Further tests have shown that plexin also encourages the formation of metastases in melanoma and pancreatic cancer, the researchers said.
If new treatments can be developed to inhibit the crucial interaction between plexin and semaphorin, it may be possible to prevent these cancers from establishing new tumors, the researchers said in a statement.
Reporting by Nancy Lapid; Editing by Bill Berkrot
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
